AngioDynamics Inc. (NASDAQ:ANGO) Q3 2024 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice President, Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Steve Lichtman - Oppenheimer & Co. John Young - Canaccord Genuity Operator Good morning and welcome to the AngioDynamics fiscal year 2024 third quarter earnings call. At this time, all participants are in a listen-only mo ...

Exhibit 99.1 PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture Fiscal Year 2024 Third Quarter Highlights • Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 o Discontinued its Uniblate and Starburst RadioFrequency products, as well as its Syntrax support ...

AngioDynamics, Inc. (ANGO) recently announced that it has entered into a settlement agreement with Becton, Dickinson and Company (BDX) , popularly known as BD, to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD.AngioDynamics is likely to benefit from the settlement of this prolonged legal dispute to a successful resolution as it will lower the company’s ongoing legal expenses and terminate more than 10-year distraction.Price PerformanceFor the past six months, ANGO’s share ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the ...

The most recent trading session ended with AngioDynamics (ANGO) standing at $5.37, reflecting a -0.74% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily loss of 0.65%. Meanwhile, the Dow experienced a drop of 0.49%, and the technology-dominated Nasdaq saw a decrease of 0.96%.The medical device maker's stock has dropped by 12.32% in the past month, falling short of the Medical sector's gain of 1.98% and the S&P 500's gain of 3.27%.The upcoming earnings relea ...

AngioDynamics (ANGO) closed at $5.67 in the latest trading session, marking a -1.39% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.65% for the day. On the other hand, the Dow registered a loss of 0.18%, and the technology-centric Nasdaq decreased by 1.16%.The the stock of medical device maker has fallen by 6.5% in the past month, lagging the Medical sector's gain of 3.18% and the S&P 500's gain of 3.4%.The investment community will be paying close attention to th ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Virtual Healthcare MedTech ...

In the latest market close, AngioDynamics (ANGO) reached $5.99, with a +1.7% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 2.11%. Elsewhere, the Dow gained 1.18%, while the tech-heavy Nasdaq added 2.96%.The the stock of medical device maker has fallen by 1.83% in the past month, lagging the Medical sector's gain of 3.98% and the S&P 500's gain of 3.08%.The investment community will be closely monitoring the performance of AngioDynamics in its forthcoming ...

AngioDynamics, Inc. (ANGO) recently announced the completion of the sale of its PICC and Midline product portfolios to Spectrum Vascular for $45 million in cash.AngioDynamics' PICC, Midline, and tip location products are the subject of the transaction. During AngioDynamics' fiscal 2023, the combined portfolio of products contributed more than $43.5 million in revenues annually.Price PerformanceFor the past six months, ANGO’s shares have declined 28.1% against the industry’s rise of 7.8%. The S&P 500 increas ...

AngioDynamics (ANGO) closed the latest trading day at $6.17, indicating a +1.31% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily gain of 0.58%. Elsewhere, the Dow gained 0.91%, while the tech-heavy Nasdaq added 0.3%.Coming into today, shares of the medical device maker had gained 3.4% in the past month. In that same time, the Medical sector gained 2.39%, while the S&P 500 gained 4.61%.Investors will be eagerly watching for the performance of AngioDynamics in ...